v3.26.1
Segment Information - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 249.7 $ 22.4 $ 265.3 $ 211.2
Less:        
Cost of license revenue 9.0 0.0 9.0 0.0
Total research and development expense 52.6 68.6 113.0 159.4
General and administrative expense 24.0 25.3 43.0 51.9
Income tax expense (benefit) 0.2 (0.3) 0.3 (0.2)
Interest income, net 5.5 10.3 11.9 22.0
Segment net income (loss) 169.4 (61.2) 111.8 21.7
Reportable Segment        
Less:        
Cost of license revenue 9.0 0.0 9.0 0.0
Non-program-specific external expense 8.5 11.1 17.7 25.0
Compensation and related personnel expense (including stock-based compensation) 17.4 28.4 38.7 65.3
Other research and development expense 2.5 4.3 4.9 7.4
Total research and development expense 52.6 68.6 113.0 159.4
General and administrative expense 24.0 25.3 43.0 51.9
Other segment expense, net 0.0 0.3 0.1 0.4
Income tax expense (benefit) 0.2 (0.3) 0.3 (0.2)
Interest income, net 5.5 10.3 11.9 22.0
Segment net income (loss) 169.4 (61.2) 111.8 21.7
Reportable Segment | Vepdegestrant ARV-471        
Less:        
Program-specific external expense 4.5 15.1 13.3 39.2
Reportable Segment | ARV-806        
Less:        
Program-specific external expense 5.6 1.7 12.1 2.6
Reportable Segment | ARV-102        
Less:        
Program-specific external expense 5.1 3.8 10.7 10.3
Reportable Segment | ARV-393        
Less:        
Program-specific external expense 4.8 2.5 8.5 5.1
Reportable Segment | ARV-027        
Less:        
Program-specific external expense 3.3 0.1 5.0 0.2
Reportable Segment | Bavdegalutamide (ARV-110)        
Less:        
Program-specific external expense (0.4) 0.9 (0.2) 2.0
Reportable Segment | Other programs        
Less:        
Program-specific external expense $ 1.3 $ 0.7 $ 2.3 $ 2.3